Publish in this journal
Journal Information
Vol. 10. Issue 6.
Pages 420-421 (November - December 2014)
Vol. 10. Issue 6.
Pages 420-421 (November - December 2014)
Letter to the Editor
DOI: 10.1016/j.reumae.2014.04.003
Full text access
Macrophage Activation Syndrome as a Severe Manifestation of Adult's Still's Disease. Hemophagocytic Cells in Ascites
Síndrome de activación macrofágica como complicación severa de la enfermedad de Still del adulto. Células hemofagocíticas en líquido ascítico
Visits
...
César Egües Dubuc
Corresponding author
tonoeguesdubuc@hotmail.com

Corresponding author.
, Miren Uriarte Ecenarro, Nerea Errazquin Aguirre, Joaquín Belzunegui Otano
Servicio de Reumatología, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Full Text
To the Editor:

Macrophage activation syndrome (MAS) occurs in a minority of patients with adult Still's disease (ASD).1,2 It can be the diseases’ first manifestation or be triggered by an infection or change in treatment.3 Two cases are presented.

The first case is a 30-year-old woman with ASD, who came to the ER with a fever lasting for one week that did not improve with antibiotics, so she was admitted to the Rheumatology department. During admission, treatment with ceftriaxone and glucocorticoids (GC) mg/kg was started, and multiple complementary tests performed: blood culture positive for pneumococcus and positive serology for cytomegalovirus; analytically: hepatitis, elevated acute phase reactants (APR), hyperferritinemia, hypertriglyceridemia, thrombocytopenia, and anemia, in addition to splenomegaly in the computed tomography (CT).

Despite treatment, evolution was unfavorable, with persistent thrombocytopenia and declining ESR. With these data, we decided to perform a bone marrow biopsy (BMB), observing hemophagocytic cells (HC), diagnosing MAS and initiating treatment with cyclosporine (CSP) 5mg/kg/day and 60GC mg/day, with progressive improvement.

The second case is a 35-year-old woman who presented with fever, a sore throat, musculoskeletal pain, vomiting and rash for a week, diagnosed as the flu. Three days later she came to the ER because of persistent fever and rash, and the onset of lymphadenopathy, and was hospitalized. During admission, treatment was started with ceftriaxone and gentamicin; associated infection and autoimmunity was ruled out. Analytically she presented: anemia, elevated APR, hepatitis, hyperferritinemia, hypertriglyceridemia, impaired renal function and ascites. A CT was performed, which reported a systemic infection with lymphadenopathy and hepatosplenomegaly.

The initial suspicion was ASD, starting GC therapy at a dose of 1mg/kg/day and presenting an initial improvement. Subsequently, the fever persisted and skin lesions progressed, added to respiratory and renal failure, which led to her transfer to the Intensive Care Unit (ICU) of our hospital. On admission to the ICU, we performed a BMB, ascites analysis, observing HC in both (Fig. 1). She was diagnosed as MAS. Evolution was poor despite GC, so we added CSP 5mg/kg/day, with partial improvement and anakinra 100mg/day. The evolution was favorable, so she was transferred to the rheumatology department, where after a few days she was discharged.

Fig. 1.

Ascites. Red cell within macrophages is observed.

(0.08MB).

Both conditions share several features, such as fever, hepatosplenomegaly, lymphadenopathy, hepatitis, coagulopathy and hyperferritinemia, and often are indistinguishable.2,3 Pleuritis, acute respiratory distress syndrome and pancytopenia are more common in the MAS1,2 and cutaneous and articular affection in ASD.2,3 Leukopenia, thrombocytopenia and hypertriglyceridemia are not common in ASD, so these could serve as warning signs1,2; Additionally, hyperferritinemia is generally higher in MAS.2,4

Most of the cases described in the literature have been treated with GC, immunoglobulins, CSP and biological drugs.1,2 Both conditions share certain pathophysiologic characteristics such as the production factor tumor necrosis α and interleukins (IL), IL-1, IL-6, IL-8 and IL-18, with these being potential therapeutic targets.5,6

The first patient probably presented MAS after a triggering infection. We hypothesize that the MAS in ASD can occur after a change in treatment or an infection; the most studied is the Epstein–Barr virus infection, but it has also been described2,3,6 in cases of cytomegalovirus.

Patient 2 presented HC in ascites; the first case was described in 2007 in a patient with liver cirrhosis and Escherichia coli infection.7 In addition, cases described with HC in8,9 pleural fluid and in cerebrospinal fluid.10

Conflict of Interest

The authors have no disclosures to make.

References
[1]
R. Dhote, J. Simon, T. Papo, B. Detournay, L. Sailler, M.H. Andre, et al.
Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review.
Arthritis Rheum, 49 (2003), pp. 633-639
[2]
J.B. Arlet, D.L. Thi Huong, A. Marinho, Z. Amoura, B. Wechsler, T. Papo, et al.
Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature.
Ann Rheum Dis, 65 (2006), pp. 1596
[3]
A. Karras, O. Hermine.
Syndrome d’activation macrophagique [Macrophage activation syndrome].
Rev Med Intern, 23 (2002), pp. 768-778
[4]
B. Fautrel, G. Le Moel, B. Saint-Marcoux, P. Taupin, S. Vignes, S. Rozenberg, et al.
Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease.
J Rheumatol, 28 (2001), pp. 322-329
[5]
J. Villanueva, S. Lee, E.H. Giannini, T.B. Graham, M.H. Passo, A. Filipovich, et al.
Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome.
Arthritis Res Ther, 7 (2005), pp. R30-R37
[6]
M. Garcia-Consuegra, R. Merino Muñoz, J. Inocencio Arocena, Grupo de Estudio del Síndrome de Activación Macrofágica y Artritis Idiopática Juvenil, de la Sociedad Española de Reumatología Pediátrica.
Síndrome de activación macrofágica y artritis idiopática juvenil. Resultados de un estudio multicentrico.
An Pediatr (Barc), 68 (2008), pp. 110-116
[7]
B. Parmentier, P. Hammel, H. Bennani, D. Valla, P. Lévy, P. Ruszniewski.
Severe thrombopenia as single sign of hemophagocytosis in a patient with cirrhosis and lethal infection of ascitis fluid by Escherichia coli.
Gastroenterol Clin Biol, 31 (2007), pp. 967-969
[8]
T. Zohreh Mohammad, R. Mohammad Mehdi, N. Seyed Alireza, M. Forouzan.
Transient localized hemophagocytosis in pleural effusion.
Tanaffos, 9 (2010), pp. 61-63
[9]
P. Zaharopoulos.
Serous fluid cytology as a means of detecting hemophagocytosis in Epstein–Barr virus-induced autoimmune hemolytic anemia.
Diagn Cytopathol, 25 (2001), pp. 248-252
[10]
M. Fathalla, J. Hashim, H. Alkindy, Y. Wali.
Cerebrospinal fluid involvement in a case of visceral leishmaniasis associated with hemophagocytic lymphohistiocytosis.
Sultan Qaboos Univ Med J, 7 (2007), pp. 253-256

Please cite this article as: Egües Dubuc C, Uriarte Ecenarro M, Errazquin Aguirre N, Belzunegui Otano J. Síndrome de activación macrofágica como complicación severa de la enfermedad de Still del adulto. Células hemofagocíticas en líquido ascítico. Reumatol Clin. 2014;10:420–421.

Copyright © 2014. Elsevier España, S.L.U.. All rights reserved
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.